Descargar

Medida de fomento de la confianza "G"

Instalaciones de producción de vacunas

LNP formulation and release testing of mRNA-based COVID-19 vaccines encoding SARS-CoV-2 antigens

Fill and finish of mRNA-based COVID-19 vaccines encoding SARS-CoV-2 antigens
Fill and finish of recombinant and adjuvanted SARS-CoV-2-antigen-based COVID-19 vaccines

Manufacture of live recombinant Ebola virus vaccines.

Develops and produces RNA vaccines encoding Rabies antigens and SARS-CoV-2 antigens.

Hepatitis B (commissioned production, no own licence for marketing)

Influenza virus vaccine for human immunisation purposes

Live Smallpox vaccines, Following Investigational Medicinal Products - live recombinant HIV vaccines, live recombinant Malaria vaccines, live recombinant and inactivated recombinant Filovirus vaccines, live recombinant Flavivirus vaccines, MERS-CoV vaccine, inactivated recombinant Lassa virus vaccine, live recombinant Rift Valley Fever Virus vaccine, live recombinant and inactivated SARS-CoV-2 vaccines and live recombinant Chikungunya vaccine

LNP formulation and release testing of mRNA-based COVID-19 vaccines encoding SARS-CoV-2 antigens.

produces mRNA vaccines encoding SARS-CoV-2 antigens

Clinical trial material only, no own licenses for marketing: Tuberculosis vaccine (recombinant and nonrecombinant). Smallpox vaccine (recombinant), Bordetella vaccine, HIV vaccine (recombinant), Zika vaccine (recombinant), Typhus vaccine, RSV, Newcastle Disease Virus (Drug Substance, recombinant), Influenza A (PR8 vaccine), VSV vaccine (recombinant), HSV-1 vaccine (recombinant), CoVid vaccine (recombinant)